MREO Investor Alert: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026

Core Viewpoint - The complaint against Mereo BioPharma alleges violations of federal securities laws due to false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints in reducing annualized clinical fracture rates compared to control groups [2] Group 1: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought and is representative of the class members [3] - Any member of the putative class can move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [3] Group 2: Whistleblower Information - The law firm encourages individuals with information regarding Mereo BioPharma's conduct, including whistleblowers and former employees, to come forward [4]